Clinical reference Biomarker Directory
Back to directory

INS

Established

Insulin, paired with C-peptide, is central to diagnosing insulinoma via a supervised fasting test.

Also known as Insulin
In plain language

Insulin lowers blood sugar. When a rare pancreatic tumor makes too much insulin, it causes dangerous low blood sugar. Doctors diagnose this with a supervised fasting test — and it turns out a shorter 48-hour fast usually works just as well as the traditional 72-hour version.

Biomarker & context

Insulin is a pancreatic beta-cell hormone that lowers blood glucose; beyond diabetes management, it is central to diagnosing insulinoma, a rare insulin-secreting pancreatic tumor causing recurrent hypoglycemia.

What it indicates

Inappropriately elevated insulin (and C-peptide) during a hypoglycemic episode confirms endogenous hyperinsulinism, most often from insulinoma; the insulin-to-C-peptide relationship also distinguishes a real tumor from factitious (self-induced) hypoglycemia, since commercial insulin injections don't contain C-peptide.

Diagnosis & clinical testing

The classic diagnostic test is a 72-hour supervised fast measuring glucose, insulin, C-peptide, and proinsulin, terminated when hypoglycemia with symptoms occurs (Whipple's triad); current practice increasingly finds a shorter 48-hour fast diagnoses 90-95% of cases, since nearly all insulinoma patients become symptomatic well before 72 hours.

Guiding treatment

Confirmed insulinoma is treated with surgical enucleation or pancreatic resection, usually curative; medical management with diazoxide or octreotide is used preoperatively or in unresectable/metastatic cases.

Clinical significance

A shorter 48-hour fast now diagnoses 90-95% of insulinoma cases, refining the older 72-hour protocol.

References
  1. StatPearls. (2025). Insulinoma.
  2. AMBOSS. Insulinoma — Diagnostic Workup.